Drugs / PTT-936
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06244992 | Jan 2024 → Dec 2025 overdue | — | Pyrotech Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PTT-936 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06244992 ↗ |
| Action | Activate | “PTT-936, an Alpha Kinase 1 (ALPK1) activator” NCT06244992 ↗ |
| Route | Oral | “PTT-936 administered per orally (PO)” NCT06244992 ↗ |
| Target | ALPK1 | “PTT-936, an Alpha Kinase 1 (ALPK1) activator” NCT06244992 ↗ |